Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic for Alzheimer's disease, has announced its plans to report second quarter 2024 financial results on August 13, 2024. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Interested parties can register for the live conference call using a provided link, which will furnish dial-in numbers and a PIN. Registration should be completed at least one day in advance. An archived version of the webcast will be available for a minimum of 30 days in the Investors section of Acumen's website.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di una nuova terapia per la malattia di Alzheimer, ha annunciato i suoi piani per riportare i risultati finanziari del secondo trimestre 2024 il 13 agosto 2024. L'azienda ospiterà una conferenza telefonica e un webcast audio dal vivo alle 8:00 a.m. ET per fornire un aggiornamento sulla situazione aziendale e finanziaria.
Le parti interessate possono registrarsi per la conferenza telefonica dal vivo utilizzando un link fornito, che conterrà numeri di accesso e un PIN. È consigliabile completare la registrazione almeno un giorno prima. Una versione registrata del webcast sarà disponibile per un minimo di 30 giorni nella sezione Investitori del sito web di Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), una compañía biofarmacéutica en etapa clínica centrada en desarrollar un nuevo tratamiento para la enfermedad de Alzheimer, ha anunciado sus planes para informar sobre los resultados financieros del segundo trimestre de 2024 el 13 de agosto de 2024. La empresa llevará a cabo una conferencia telefónica y un webcast de audio en vivo a las 8:00 a.m. ET para proporcionar una actualización sobre el negocio y la situación financiera.
Las partes interesadas pueden registrarse para la conferencia telefónica en vivo utilizando un enlace proporcionado, que facilitará los números de marcado y un PIN. Se recomienda completar el registro al menos un día antes. Una versión grabada del webcast estará disponible durante un mínimo de 30 días en la sección de Inversores del sitio web de Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS)은 알츠하이머병에 대한 새로운 치료제를 개발하는 데 중점을 둔 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 13일에 발표할 계획이라고 발표했습니다. 회사는 오전 8:00 ET에 비즈니스 및 재무 업데이트를 제공하기 위해 전화 회의와 라이브 오디오 웹캐스트를 개최할 것입니다.
관심 있는 분들은 제공된 링크를 사용하여 라이브 회의에 등록할 수 있으며, 이 링크는 다이얼 인 번호와 PIN을 제공합니다. 등록은 최소 하루 전에 완료하는 것이 좋습니다. 웹캐스트의 기록된 버전은 Acumen의 웹사이트 투자자 섹션에서 최소 30일 동안 제공될 것입니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une entreprise biopharmaceutique en phase clinique axée sur le développement d'un nouveau traitement pour la maladie d'Alzheimer, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le 13 août 2024. L'entreprise organisera une conférence téléphonique et un webinaire audio en direct à 8h00 ET pour fournir une mise à jour sur ses activités et ses finances.
Les parties intéressées peuvent s'inscrire pour participer à la conférence en direct en utilisant un lien fourni, qui fournira les numéros d'accès et un code PIN. Il est recommandé de compléter l'inscription au moins un jour à l'avance. Une version archivée du webinaire sera disponible pendant un minimum de 30 jours dans la section Investisseurs du site Web d'Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung einer neuartigen Therapie für Alzheimer-Krankheit konzentriert, hat angekündigt, seine Finanzergebnisse für das zweite Quartal 2024 am 13. August 2024 bekanntzugeben. Das Unternehmen wird eine Telefonkonferenz und ein Live-Audio-Webcast um 8:00 Uhr ET veranstalten, um ein Update zu den Geschäftszahlen und der finanziellen Situation zu geben.
Interessierte Parteien können sich über einen bereitgestellten Link für die Live-Konferenz anmelden, der Einwahlnummern und eine PIN zur Verfügung stellt. Die Registrierung sollte mindestens einen Tag im Voraus abgeschlossen werden. Eine archivierte Version des Webcasts wird für mindestens 30 Tage im Investorenbereich der Website von Acumen verfügbar sein.
- None.
- None.
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (ABOS) report its Q2 2024 financial results?
What time is Acumen Pharmaceuticals' (ABOS) Q2 2024 earnings call scheduled for?
How can investors participate in Acumen Pharmaceuticals' (ABOS) Q2 2024 earnings call?
Where can investors find the archived webcast of Acumen Pharmaceuticals' (ABOS) Q2 2024 earnings call?
